FDA PCAC July 2026: What The Peptide Committee Decided

What did the FDA ask the committee to decide?

What were the fourteen questions, and what did FDA propose?

The FDA's briefing document for the meeting sets out the task. The agency considered seven peptides, each in its free base and acetate forms, as fourteen separate bulk drug substances: BPC-157, KPV, TB-500, and MOTS-c on July 23; emideltide (DSIP), Epitalon, and Semax on July 24. For each of the fourteen, the document lists a "point to consider," and each one reads the same way: the FDA is proposing that the substance not be included on the 503A bulks list.

The same document states the legal frame in one sentence. The FDA does not intend to issue a final determination until it has considered the committee's input and finalized all of its reviews, and that determination may be affected by issues not discussed at the meeting.

The committee also wasn't voting on the peptides in the abstract. It was voting on each substance for the specific use the FDA had evaluated, which the meeting page lists: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory skin conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, DSIP for opioid withdrawal, chronic insomnia, and narcolepsy, Semax for cerebral ischemia, migraine, and trigeminal neuralgia, and Epitalon for insomnia. If you've heard the vote described as "BPC-157 for healing," that isn't what was on the ballot.

What four criteria does FDA use for the bulks list?

The FDA evaluates every candidate for the 503A bulks list against four criteria set out in its February 2019 final rule, the first rule for the list (21 CFR 216.23): the physical and chemical characterization of the substance; any safety issues raised by its use in compounding; the available evidence of effectiveness or lack of effectiveness; and its historical use in compounded products. The agency applies them as a balancing test, substance by substance, and its staff walked the committee through all four for each peptide.

How the bulks list relates to the interim categories that most clinicians have heard about, and what happened to the five peptides the committee reviewed in 2024, is covered on Scriptura's federal peptide rules page.

Why did the FDA review peptides whose nominations were withdrawn?

The briefing document's footnotes show that every nomination for all seven peptides came from one of two sources: LDT Health Solutions, on behalf of the International Peptide Society, and Wells Pharmacy Network. And every one of those nominations had been withdrawn before the meeting. For each substance, the document carries the same note: the nomination was withdrawn by the nominator; however, the FDA is electing to proceed with the presentation to the committee.

That matters for two reasons. The withdrawals are what took the twelve peptides out of Category 2 in April; the FDA's list changes when a nominator withdraws, not when the agency changes its mind. And the FDA's choice to evaluate the substances anyway is the same choice it made in 2024, when it presented CJC-1295, AOD-9604, and thymosin alpha-1 to the committee after their nominators had withdrawn, and the committee voted all three down. Where each of the twelve stands today, and what the FDA has written about each, is tracked on Scriptura's federal timeline for peptide compounding.

What did FDA scientists argue?

The staff case came in three parts. It's in the July 23 and July 24 presentation decks and in a separate FDA briefing document for each peptide, linked below.

The first part was identity. An FDA regulatory affairs official opened both days with a presentation on what he called conflated bulk substances and common-name challenges: nominations that use trade or common names instead of chemical ones, so that it isn't clear what is being nominated, compounded, or dosed. Different salts and the free base of the same molecule are distinct substances under the statute with different stability, solubility, and toxicity, and the FDA has encountered multiple salts and derivatives sold under the same common name, CJC-1295 being the example given. NPR's report from the meeting quoted an FDA official summarizing the problem: "We can't create quality standards until we actually know what it is."

The second part was evidence, and it was thinner than most prescribers assume. For BPC-157, the FDA's briefing document found a single human trial in ulcerative colitis, 53 subjects treated with a rectal enema, reported only as a 2005 meeting abstract, with a difference between arms whose confidence interval crossed zero. It found no studies at all by the oral, subcutaneous, nasal, or transdermal routes the nominators proposed, and a 28-day toxicity study in rats and dogs showing coagulation and liver signals.

For KPV, TB-500, and MOTS-c, the FDA identified no clinical studies or human exposure data by any route. For DSIP, the human evidence was a handful of small intravenous studies from the 1980s with conflicting results and nothing for the subcutaneous route nominated.

For Epitalon, there were no publications on efficacy in insomnia and no studies by the proposed route. For Semax, the FDA found one small uncontrolled study in which the substance was not effective for most subjects with migraine or trigeminal neuralgia, and seven references in Russian that it could not evaluate.

The third part was safety, and the pattern was an absence. The FDA's conclusion for most of the seven was that it lacked the information to know whether the substance would cause harm, with an immunogenicity concern from aggregation and impurities for anything given by injection or nasal spray. Where it had findings, they were specific: the coagulation signals for BPC-157; a telomere-lengthening mechanism for Epitalon that raises a theoretical concern about cells evading senescence under chronic exposure; an antithrombotic property reported for Semax that raises a bleeding question; a finding that Semax potentiates amphetamine-induced striatal dopamine release in mice.

For every one of the seven, the FDA's evaluation ended with the same balancing conclusion: the criteria weigh against inclusion, and FDA-approved therapies exist for the condition evaluated.

Two points from the agency's introductory remarks frame all of that and are worth carrying into any conversation about what the vote proved. First, the FDA said plainly that information on dispensing or patient use is not the same thing as real-world evidence about a product's benefits or risks. The argument that a peptide must be safe because thousands of clinics prescribe it was anticipated and rejected before the first substance was discussed.

Second, compounders operating under 503A are not required to report adverse events to the FDA. The absence of reports in the agency's database, which the staff noted for KPV, TB-500, MOTS-c, DSIP, and Epitalon, was presented with the caveat that it does not imply safety. A prescriber who reads "no FAERS reports" as reassurance is reading it the way the FDA specifically said not to.

How did the committee vote on each peptide?

The counts below are as reported; the FDA's final summary minutes are pending. The FDA's own record for now is the archived webcast of both days, linked from the meeting page. The BPC-157, KPV, TB-500, MOTS-c, and DSIP counts are from AJMC and McDermott Will & Emery's account. AJMC gives no numbers for Semax or Epitalon. For those two, McDermott and RAPS Regulatory Focus agree on Semax's 8 to 5 and differ on Epitalon. The counts will be replaced with the FDA's figures when the minutes post.

Day one was four substances, four narrow margins, and abstentions on every vote. Day two produced the meeting's only rejection: DSIP, 6 to 7. Semax passed 8 to 5 and Epitalon 7 to 4 or 7 to 5, depending on the report. Why that one differed from the other six is something the minutes will record; the reporting from the room doesn't settle it, and this page won't guess.

Who sat on the July 2026 committee?

The FDA published the names of eight new committee members on June 29, 2026, 24 days before the meeting, as STAT reported that day. The FDA's meeting roster lists each member and affiliation. On July 17, the Washington Post reported that as the panel was being assembled, FDA officials had expressed concern about appointing people who worked for peptide-related businesses and clinics.

NPR's coverage of the meeting said most of the new members had ties to the peptide industry, including physicians working for practices and companies that promote the products. An HHS spokesperson told NPR that all members underwent the standard ethics review and vetting process. Later, an analysis from the Johns Hopkins Bloomberg School of Public Health went further, saying the votes tracked with whether members had those ties.

The Washington Post reported that at least seven of the new members had ties to peptide businesses or clinics. This page does not name members.

A recommendation from an FDA advisory committee is persuasive because of who makes it. If the composition of the committee is itself a documented controversy, the recommendation carries that controversy with it wherever it's cited. A state board, a malpractice carrier, or opposing counsel will have read the Post, NPR, and Johns Hopkins. A prescriber who cites the July vote should assume they have.

Is a PCAC recommendation binding, and what happens next?

The recommendation is not binding. The FDA's meeting page says advisory committees make non-binding recommendations, which the agency generally follows but is not legally bound to. And the briefing document, as quoted above, says no determination issues until the agency finishes its reviews.

For any of the six to reach the 503A bulks list, the FDA has to propose a rule, take public comment, and finalize it. That is the same path the agency followed for its first bulk-list rule in February 2019, and in that rule it declined four substances the committee had reviewed.

Buchanan Ingersoll & Rooney's post-vote analysis lays out what the agency now has to work through: how to respond to the recommendations, whether more evidence or safeguards are needed, whether the interim enforcement posture should change, and when rulemaking starts. As of Frier Levitt's September update, the FDA has made no determination, published no proposed rule, and announced no change to its enforcement posture.

McDermott Will & Emery expects the FDA to exercise informal enforcement discretion for the six recommended substances while rulemaking runs. That is a law firm's expectation. It is not an FDA statement, and a pharmacy that compounds on the strength of it is taking the risk itself.

One more procedural point from the FDA's own introductory remarks. When a substance is placed on the 503A bulks list, it can be compounded for any use and by any route unless the entry carries a limitation. So a rule adding BPC-157, if one ever came, would not add BPC-157 for ulcerative colitis. It would add BPC-157. The committee evaluated one indication; the list doesn't work by indication.

The FDA also pointed, on both days, to the pathway it considers the right one for substances like these: an investigational new drug application, which provides patient access to a specified, well-characterized substance and generates the safety and effectiveness data the bulk-list process was not designed to produce. Compounders can use that pathway. None of the nominators had.

The vote does not change a prescriber's other exposures (the state board, the carrier, a civil claim). For the state side, see Scriptura's state-by-state prescribing rules.

What should you know before you cite the vote?

The July vote will come up in three places: in a consent conversation, in a chart note, and in a response to a board or a carrier. In each, the question is the same. What does the record show you knew?

If your rationale for a peptide decision includes the committee's recommendation, the record should also show what you knew. The FDA's scientists proposed against every substance. The human evidence for most of them was absent or a single small study. The committee was reconstituted 24 days before the meeting, and its composition was reported as a conflict-of-interest question. And the FDA has not acted.

A note that says "PCAC recommended BPC-157 in July 2026" is a headline. A note that says all of the above and then explains why you proceeded anyway is a clinical judgment.

The vote also doesn't touch the parts of the record that a board looks at first. The Alabama Board of Medical Examiners' May 2026 notice prohibits research-grade peptides without reference to any federal committee, and no state board has said a committee vote changes its position. Your source, your consent language, and your monitoring plan are the same questions they were on July 22.

The committee meets again before the end of February 2027, and neither the FDA's response to the July votes nor the final minutes has a posted date.

Where can I read the meeting record?

The FDA has posted the meeting's documents on its event page. The introductory briefing document carries the fourteen proposals and the withdrawn-nomination footnotes. Separate briefing documents for each of the seven peptides carry the full FDA evaluation: BPC-157, DSIP, Epitalon, KPV, MOTS-c, Semax, and TB-500.

The FDA's presentation decks for July 23 and July 24 are the slides its staff presented in the room. The public docket, FDA-2025-N-6895, holds written comments on Regulations.gov. Archived webcasts of both days are linked from the event page.

The FDA's final summary minutes, the document that records each vote and the members' stated reasoning, had not been posted as of October 19, 2026. We update this section when they appear.

What happens at the February 2027 session?

Five more of the peptides removed from Category 2 in April are scheduled for the committee's next session: cathelicidin LL-37, Dihexa acetate, injectable GHK-Cu, Melanotan II, and PEG-MGF. The FDA's April 16, 2026 Federal Register notice says that session will be held before the end of February 2027, and Goodwin's May note names the five.

The agency's published concerns for those five, on its safety-risks page, are, if anything, more specific than for the July seven: nonclinical findings on male reproduction and tumor promotion for LL-37, and case reports of melanoma and posterior reversible encephalopathy syndrome for Melanotan II. Whether the committee that hears them is the same committee that voted in July is one of the things worth watching.

Frequently asked questions

How do you track the FDA's next move on peptides?

We update this page when the FDA responds, when the minutes post, and after the February session.

If your chart currently records the committee vote but not what the FDA's scientists said, book a short demo to see how Scriptura structures the evidence base for a peptide decision around the whole patient. Clinicians verify their license before platform access.

Related articles

• Federal timeline for peptide compounding
• BPC-157 clinician reference
• Peptide rules in Alabama

Get FDA and state board changes by email: subscribe to Scriptura Clinical Intelligence.

About the author